Business Wire

Helical Fusion Signs Japan’s First Power Purchase Agreement for Fusion Energy with Aoki Super

8.12.2025 10:00:00 CET | Business Wire | Press Release

Share

Helical Fusion Co., Ltd. (Headquarters: Tokyo, Japan; “Helical Fusion”), a company developing a commercially viable Helical Stellarator power plant under its “Helix Program”, has signed a Power Purchase Agreement (PPA) with Aoki Super Co., Ltd. (Headquarters: Aichi, Japan; “Aoki Super”), a major regional supermarket chain in central Japan.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207372064/en/

Takaya Taguchi (left), CEO of Helical Fusion Co., Ltd. , and Masayuki Kono (right) Managing Director and Head of Administration Division of Aoki Super Co., Ltd. at the press conference held on December 8, 2025

This marks the first fusion-energy PPA ever signed in Japan, representing a concrete step forward in the real-world adoption of fusion energy and signaling growing demand-side engagement in the emerging fusion energy value chain.

Significance of This Agreement

Fusion energy—generated by reproducing on Earth the same nuclear fusion reactions that power the sun—is widely expected as a high-efficiency, sustainable energy source. Since the concept was proposed in the 1930s, global attention has focused primarily on the scientific and technical challenges of realizing fusion. However, for fusion to become part of real-world energy infrastructure, the presence of customers willing to procure fusion-generated electricity and to integrate it into their long-term decarbonization strategies is essential.

Under the Helix Program, Helical Fusion begins with a simple premise: fusion must function as a reliable power source. Working backward from this goal, the company defined three non-negotiable requirements—steady-state operation, net electricity, and maintainability—and selected the Helical Stellarator as the only design capable of meeting all three with existing technology. Helical Fusion’s approach is grounded in over 60 years of Japanese national fusion research, enabling the company to outline a credible technical pathway to continuous, net-electricity operation.

The newly signed PPA demonstrates that this development plan has been concretely evaluated by a real electricity consumer: Aoki Super, which requires large amounts of electricity every day to operate its store networks. Both companies share the view that fusion energy can underpin environmentally responsible retail operations that support everyday life.

The agreement is also an important milestone for the Helix Program, whose distinctive strength lies in mobilizing Japan’s entire industrial value chain—from advanced manufacturing to end-users—to accelerate the realization of fusion energy.

About Aoki Super Co., Ltd.

Founded in 1941 and headquartered in Nagoya, Aoki Super operates 50 community-based supermarkets across Aichi Prefecture, Japan. As a food retailer operating electricity-intensive stores, the company views climate change—such as shifting agricultural production regions and rising seawater temperatures affecting marine resources—as a critical challenge.

In July 2025, as part of its long-term commitment to sustainability and environmental stewardship, Aoki Super made a strategic investment in Helical Fusion.

About Helical Fusion Co., Ltd.

Helical Fusion is a Japan-based fusion company developing the world’s first commercially viable, net-electricity fusion power plant, leveraging the Helical Stellarator and inheriting more than 60 years of national fusion research.

To date, Helical Fusion has raised JPY 5.2 billion (≈ USD 34 million) in equity funding, bringing its cumulative fundraising—including grants and loans—to approximately USD 38 million (≈ JPY 6.0 billion).

​​About the Helix Program

The Helix Program targets the launch of the world’s first commercially viable fusion power plant in the 2030s through its Fusion Pilot Plant, Helix KANATA. The program defines three essential requirements for commercially viable fusion power:

Steady-state operation: 24/7/365 stable performance

Net electricity output: generating more energy than it consumes

Maintainability: regular, efficient component maintenance

The Helical Stellarator is uniquely capable of meeting all three criteria with existing technologies. The Helix Program aims to be the world’s first initiative to realize all of these requirements by the 2030s.

Company Details

View source version on businesswire.com: https://www.businesswire.com/news/home/20251207372064/en/

Contacts

Media Contact
Email: contact@helicalfusion.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press Release

Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima

Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 16:25:00 CEST | Press Release

Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensuring your investment is delivering.” The rapid growth of the residential solar market created a growing population of “orphaned” solar sy

Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press Release

A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press Release

Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press Release

Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye